DDInter909 DDInter1435
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Imatinib {u} (Compound) resembles {v} (Compound) Buclizine
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Imatinib {u} (Compound) binds {v} (Gene) CA12
Imatinib {u} (Compound) upregulates {v} (Gene) MEF2C
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
Imatinib {u} (Compound) causes {v} (Side Effect) Eye disorder
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Imatinib (Compound) resembles Buclizine (Compound)
Imatinib (Compound) treats hematologic cancer (Disease)
Imatinib (Compound) binds CA12 (Gene)
Imatinib (Compound) upregulates MEF2C (Gene)
Imatinib (Compound) downregulates DECR1 (Gene)
Imatinib (Compound) causes Eye disorder (Side Effect)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Citalopram
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab